Variability in fluorouracil exposure during continuous intravenous infusion

Int J Clin Pharmacol Ther. 2012 Jan;50(1):82-4. doi: 10.5414/cpp50082.

Authors

Tomi Hendrayana¹, Verena Kurth, Linda Krolop, Paul Kenny, Ralf Axel Hilger, Ingo G H Schmidt-Wolf, Yon-Dschun Ko, Ulrich Jaehde

Affiliation

¹ Institute of Pharmacy, Clinical Pharmacy, Center for Integrated Oncology (CIO), University of Bonn, and Department of Oncology, Internal Medicine, Johanniter Hospital, Bonn, Germany.

PMID: 22192656
DOI: 10.5414/cpp50082

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antimetabolites, Antineoplastic / administration & dosage
Antimetabolites, Antineoplastic / pharmacokinetics*
Antimetabolites, Antineoplastic / therapeutic use
Area Under Curve
Body Surface Area
Dose-Response Relationship, Drug
Drug Monitoring
Feasibility Studies
Fluorouracil / administration & dosage
Fluorouracil / pharmacokinetics*
Fluorouracil / therapeutic use
Humans
Infusions, Intravenous
Neoplasms / drug therapy*
Neoplasms / pathology

Substances

Antimetabolites, Antineoplastic
Fluorouracil